Vironexis Biotherapeutics
California
About Vironexis Biotherapeutics
Vironexis will implement the cutting-edge technique of AAV-delivered T-cell immunotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $26.0M
- Funding stage: Seed
- Last round: Seed (Sep 2024)
- Website: vironexis.com
- Phone: +1 908-938-6019
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/vironexis-biotherapeutics-96338 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.